Business
Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January
NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company
About this update from Solana Company
[{"type":"text","content":"NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in January: The Demy-Colton Digital Medicine and Medtech Showcase 2021, which is being held virtually from January 11th-15th. The Company’s presentation will be available on-demand beginning on Wednesday, January 6th at 8:30 a.m. Eastern Time. The H.C. Wainwright BioConnect Conference, which is being held virtually from January 11th-14th. The Company’s presentation will be available on-demand beginning on Monday, January 11th at 6:00 a.m. Eastern Time. The Sidoti Winter 2021 Investor Conference, which is being held virtually from January 13th-14th. Management will present on Wednesday, January 13th at 1:45 p.m. Eastern Time. The ICR Conference 2021, which is being held virtually from January 11th-14th. Management will present on Thursday, January 14th at 10:45 a.m. Eastern Time. Webcasts of the presentations will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Archives of the webcasts will be available for replay following the conference. About Helius Medical Technologies, Inc. Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com. About the PoNS™ Device and PoNS Treatment™ The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currentl...